On October 24, 2023, BioNova Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to its product BN104 for the treatment of relapsed/refractory acute leukemia.

The Drug Evaluation Center of the NMPA in China announced on Oct 24, 2023, on its official site, that Innovent Biologics' Category 1 new drug, GFH925 (IBI351), is slated for priority review.

Arvinas Inc. recently reported positive results for its AR-targeting protein degraders, bavdegalutamide (ARV-110) and ARV-766, in Phase 1/2 trials for mCRPC treatment at ESMO.

Immutep recently introduced its novel LAG-3 immunotherapy, Eftilagimod Alpha (Efti), for cancer and autoimmune disease treatment at the 2023 ESMO meeting. It presented positive data from two trials for Efti with pembrolizumab ± double chemotherapy as first-line NSCLC treatments.

Inxmed Co. announced that the significant clinical research results of its independently developed core product, Ifebemtinib (IN10018), the world's first small molecule FAK inhibitor.

Dizal Pharmaceutical'S EGFR inhibitor named Sunvozertinib for first-line treatment of EGFR exon20ins mutation type advanced NSCLC, debuted at the 2023 European Society for Medical Oncology (ESMO) meeting.

On Oct 22, 2023, Amgen published results from their CodeBreaK 300 study on Lumakras and Vectibix's efficacy in treating chemo-resistant mCRC with KRAS G12C mutation.

Shanghai Huaota Biopharmaceutical's HB0034 anti-IL-36R monoclonal antibody injection was granted orphan drug designation by the U.S. FDA for the treatment of generalized pustular psoriasis (GPP).

The 2023 ESMO congress selected Shanghai Junshi Biosciences' phase III trial, EXTENTORCH, on anti-PD-1 monoclonal antibody toripalimab for the LBA.

The GEMSTONE-303 Phase III trial of CStone Pharmaceuticals' sugemalimab was selected for an LBA report at the 2023 ESMO conference.

Recently, Sanofi announced the latest data from the Phase 3 clinical trial named PROTECT for Tzield (teplizumab).

Recently, AstraZeneca announced that the National Medical Products Administration (NMPA) of China has approved C5 complement inhibitor Eculizumab for the treatment of adults.